Ozempic, also known as semaglutide, is a medication primarily used to treat type 2 diabetes. However, it has also been studied for its potential benefits in cardiovascular health [1]. Research has shown that Ozempic can reduce the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or multiple cardiovascular risk factors [2].

What sets Ozempic apart from other cardiovascular medications is its unique mode of action. It works by mimicking the action of a natural hormone called glucagon-like peptide-1 (GLP-1), which is released in response to food intake. GLP-1 helps to regulate blood sugar levels by facilitating the release of insulin and inhibiting the release of glucagon [3]. By acting on the GLP-1 receptor, Ozempic stimulates the pancreas to release more insulin and reduces glucagon levels, resulting in improved glycemic control [4].

In addition to its effects on blood sugar, Ozempic has also been shown to have a number of cardiovascular benefits, including the reduction of blood pressure, triglycerides, and LDL ("bad") cholesterol [5]. These effects are thought to be due in part to Ozempic's ability to slow the return of food from the stomach to the small intestine, which can help to reduce the peak level of glucose and insulin released during meals [6].

According to DrugPatentWatch.com [7], Ozempic was approved by the US FDA in 2017 for the treatment of type 2 diabetes, and it is marketed by Novo Nordisk [8].

Sources:

[1] https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-options-patients-type-2-diabetes
[2] https://www.nejm.org/doi/10.1056/NEJMoa2027736
[3] https://pubmed.ncbi.nlm.nih.gov/29439196/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431242/
[5] https://pubmed.ncbi.nlm.nih.gov/31055544/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424111/
[7] https://www.drugpatentwatch.com/drug/ozempic-semaglutide-10-ug-mono-preparation
[8] https://www.novo-nordisk.com/our-products/ozempic-semaglutide-injection